No Data
No Data
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also
Neumora Therapeutics, Inc. (NMRA) Gets a Buy From Bank of America Securities
Analysts Are Bullish on These Healthcare Stocks: Neumora Therapeutics, Inc. (NMRA), IDEAYA Biosciences (IDYA)
Neumora Therapeutics | 10-Q: Quarterly report
Neumora Therapeutics 1Q Loss/Shr 34c >NMRA
Neumora Therapeutics 1Q Loss/Shr 34c >NMRA
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
Neumora Therapeutics Reports Q1 Cash, Cash Equivalents And Marketable Securities Of $423M, Which Is Expected To Support Operations Into 2026
No Data